Defining trained immunity and its role in health and disease

Mihai G. Netea1,2,3✉, Jorge Domínguez-Andrés1,2, Luis B. Barreiro4,5,6, Triantafyllos Chavakis7,8, Maziar Divangahi9,10,11, Elaine Fuchs12, Leo A. B. Joosten1,2, Jos W. M. van der Meer1,2, Musa M. Mhlanga15,16, Willem J. M. Mulder15,16,17, Niels P. Riksen1,2, Andreas Schlitzer18, Joachim L. Schultze3, Christine Stabell Benn19, Joseph C. Sun20,21,22, Ramnik J. Xavier23,24 and Eicke Latz25,26,27✉

Abstract | Immune memory is a defining feature of the acquired immune system, but activation of the innate immune system can also result in enhanced responsiveness to subsequent triggers. This process has been termed ‘trained immunity’, a de facto innate immune memory. Research in the past decade has pointed to the broad benefits of trained immunity for host defence but has also suggested potentially detrimental outcomes in immune-mediated and chronic inflammatory diseases. Here we define ‘trained immunity’ as a biological process and discuss the innate stimuli and the epigenetic and metabolic reprogramming events that shape the induction of trained immunity.

Pattern recognition receptors

Pattern recognition receptors (PRRs) recognize diverse pathogen-associated molecular patterns — evolutionarily conserved structures associated with pathogens such as viruses, bacteria, fungi and parasites — and damage-associated molecular patterns, which are exposed in damaged host tissues. There are four main families of PRRs: namely, Toll-like receptors, NOD-like receptors, C-type lectin receptors and RIG1-like receptors. Interaction of pathogen-associated molecular patterns with pattern recognition receptors mediates recognition of pathogens and triggers inflammation.

The vertebrate immune system has traditionally been divided into innate and adaptive arms. Cells of the innate immune system recognize pathogens and tissue damage through germline-encoded pattern recognition receptors (PRRs), which sense diverse pathogen-associated molecular patterns and damage-associated molecular patterns. The processes activated on engagement of PRRs are rapid, are considered to be non-specific and include responses such as phagocytosis, cell locomotion, killing of pathogens or cells, and cytokine production. These innate immune mechanisms are usually very effective in eliminating invading pathogens. Additionally, dendritic cells (DCs) and specialized T cells and B cells drive adaptive immune responses, which can be concomitantly induced. These lymphocyte-dependent adaptive immune responses are slower to develop but are antigen specific and lead to long-term immunological memory.

For a long time it was assumed that immunological memory was an exclusive hallmark of the adaptive immune response. However, a growing body of literature indicating that innate immune cells — and even tissue-resident stem cells — can show adaptive characteristics has challenged this dogma. Greater protection against reinfection — a de facto immune memory function — has also been reported in plants and invertebrates, which lack an adaptive immune system. This demonstrates that adaptation of host defence can occur on the basis of innate-like immune mechanisms. Moreover, certain infections and vaccinations can induce broad protection against other pathogens through innate immune mechanisms. Conversely, the phenomenon called ‘LPS tolerance’, which can be induced by low doses of lipopolysaccharide (LPS) and other Toll-like receptor ligands, is also an adaptation of cellular responses to an external stimulus, but which leads to a lower inflammatory response to a second stimulation.

These studies have led to the hypothesis that the innate immune system also exhibits adaptive characteristics, a property that has been termed ‘trained immunity’. Understanding the properties of trained immunity will result in a better understanding of host defence mechanisms and the pathogenesis of immune-mediated diseases. The conceptual and mechanistic advances in this emerging field of science will open new avenues for clinical applications in vaccination as well as for disease prevention and treatment. In this Review, we discuss the latest discoveries in the field of trained immunity and highlight possible directions of future research in this field.

Defining trained immunity

The concept of trained immunity describes the long-term functional reprogramming of innate immune cells, which is evoked by exogenous or endogenous insults and which leads to an altered response towards a second challenge after the return to a non-activated state. The secondary response to the subsequent non-specific stimulus can be altered in such a way that the cells respond more or less strongly than to the primary response, conferring context-adjusted and time-adjusted responses. It is important to underline that trained immunity represents the concept of long-term adaptation of innate

Pattern recognition receptors

(PRРs). Germline-encoded receptors that recognize pathogen-associated molecular patterns — evolutionarily conserved structures associated with pathogens such as viruses, bacteria, fungi and parasites — and damage-associated molecular patterns, which are exposed in damaged host tissues. There are four main families of PRRs: namely, Toll-like receptors, NOD-like receptors, C-type lectin receptors and RIG1-like receptors. Interaction of pathogen-associated molecular patterns with pattern recognition receptors mediates recognition of pathogens and triggers inflammation.

The vertebrate immune system has traditionally been divided into innate and adaptive arms. Cells of the innate immune system recognize pathogens and tissue damage through germline-encoded pattern recognition receptors (PRRs), which sense diverse pathogen-associated molecular patterns and damage-associated molecular patterns. The processes activated on engagement of PRRs are rapid, are considered to be non-specific and include responses such as phagocytosis, cell locomotion, killing of pathogens or cells, and cytokine production. These innate immune mechanisms are usually very effective in eliminating invading pathogens. Additionally, dendritic cells (DCs) and specialized T cells and B cells drive adaptive immune responses, which can be concomitantly induced. These lymphocyte-dependent adaptive immune responses are slower to develop but are antigen specific and lead to long-term immunological memory.

For a long time it was assumed that immunological memory was an exclusive hallmark of the adaptive immune response. However, a growing body of literature indicating that innate immune cells — and even tissue-resident stem cells — can show adaptive characteristics has challenged this dogma. Greater protection against reinfection — a de facto immune memory function — has also been reported in plants and invertebrates, which lack an adaptive immune system. This demonstrates that adaptation of host defence can occur on the basis of innate-like immune mechanisms. Moreover, certain infections and vaccinations can induce broad protection against other pathogens through innate immune mechanisms. Conversely, the phenomenon called ‘LPS tolerance’, which can be induced by low doses of lipopolysaccharide (LPS) and other Toll-like receptor ligands, is also an adaptation of cellular responses to an external stimulus, but which leads to a lower inflammatory response to a second stimulation.

These studies have led to the hypothesis that the innate immune system also exhibits adaptive characteristics, a property that has been termed ‘trained immunity’. Understanding the properties of trained immunity will result in a better understanding of host defence mechanisms and the pathogenesis of immune-mediated diseases. The conceptual and mechanistic advances in this emerging field of science will open new avenues for clinical applications in vaccination as well as for disease prevention and treatment. In this Review, we discuss the latest discoveries in the field of trained immunity and highlight possible directions of future research in this field.

Defining trained immunity

The concept of trained immunity describes the long-term functional reprogramming of innate immune cells, which is evoked by exogenous or endogenous insults and which leads to an altered response towards a second challenge after the return to a non-activated state. The secondary response to the subsequent non-specific stimulus can be altered in such a way that the cells respond more or less strongly than to the primary response, conferring context-adjusted and time-adjusted responses. It is important to underline that trained immunity represents the concept of long-term adaptation of innate
immune cells rather than a particular transcriptional or functional programme: indeed, different stimuli (for example, β-glucan, LPS or the bacillus Calmette–Guérin (BCG) vaccine) can induce different trained immunity programmes.

In contrast to adaptive immune responses, epigenetic reprogramming of transcriptional pathways — rather than gene recombination — mediates trained immunity (Fig. 1). The immunological phenotype of trained immunity has been proven to last at least 3 months and up to 1 year, although heterologous protection against infections induced by live vaccines can last for up to 5 years11. However, even considering this, trained immunity is generally reversible and shorter lived than classical epitope-specific adaptive immunological memory12,13. Importantly however, recent studies have suggested transgenerational effects through induction of trained immunity14,15.

**Immune memory: an evolutionary perspective**

The adaptive immune system, in which T cells and B cells mediate immunological memory, has developed relatively recently in vertebrates (that is, around 500 million years ago). By contrast, invertebrate species rely solely on the innate immune system for defence against pathogens and recognition of tissue damage. In vertebrates, on encounter with a threat and activation of particular lymphocyte clones that recognize specific antigens from the invading pathogens, de novo rearrangement of immunoglobulin and T cell receptor gene segments occurs. This ‘on demand’ production of novel and diverse receptors forms the basis for lymphocyte-mediated specific immune memory responses in jawed vertebrates (the gnathostomes)16. An alternative adaptive immune system evolved in jawless vertebrates, in which specific lymphocyte-mediated immunological memory is mediated by variable lymphocyte receptors generated via the somatic rearrangement of gene elements encoding leucine-rich repeat motifs17. Both immunoglobulin-based and variable lymphocyte receptor-based adaptive immune processes in highly differentiated immune cells (that is, memory T cells and B cells or gnathostome lymphocytes) induce a recall immune response to the previously encountered pathogen that is both stronger and highly specific to the pathogen, ensuring improved survival of the organism.

Given the evolutionary success of organisms lacking adaptive immune responses, which represent up to 97% of the total biodiversity on Earth18, it is unlikely that immunological memory has evolved only in vertebrates. Indeed, over the past two decades, an increasing number of studies have provided evidence that the immune system of plants and invertebrates may be ‘primed’ by an initial infection, leading to protection against subsequent infections19,20. Likewise, memory characteristics in the innate immune system of vertebrates have recently been described and referred to as ‘trained immunity’, a process that results in a heightened reaction to secondary infections or sterile triggers of inflammation21,22. Although trained immunity is controlled by distinctive mechanisms and is less specific and of shorter duration than adaptive immune memory23, both fulfil the same principal function: a quicker and stronger response against pathogens and improved survival of the host.

**Trained immunity in vertebrates**

*Evidence of trained immunity in mouse infection models.* Many studies in mice have documented the existence of adaptive characteristics of innate immunity. Together, these studies demonstrated that training mice with different microbial ligands could protect against subsequent lethal infection in a non-specific manner. For example, treatment with the fungal ligand β-glucan protected against subsequent infection with *Staphylococcus aureus*24,25, while the peptidoglycan component muramyl dipeptide induced protection against *Streptococcus pneumoniae* and *Toxoplasma gondii* infections26. Other examples include CpG oligodeoxynucleotide application,
which leads to protection against subsequent experimental sepsis and *Escherichia coli* meningitis, or flagellin-induced protection against *S. pneumoniae* and rotavirus.

These data suggest that infections by themselves or the exposure of the immune system to microorganism-derived immune stimulatory agents can provoke not only specific protection against reinfection but also non-specific protection against a subsequent challenge with the same or another pathogen. For example, vaccination with the BCG vaccine was shown to protect animals against secondary infections with *Candida albicans*, *Schistosoma mansoni* and *Mycobacterium tuberculosis*. The non-specific character of the protection argues against a significant role of adaptive immunity for mediating this type of cross protection and suggests activation of rather non-specific protective innate immune mechanisms. The BCG vaccine also protects against lethal candidiasis in SCID mice, which lack functional T cells and B cells. Similarly, a prior mild infection with *C. albicans* protects against the subsequent exposure to a normally lethal candidiasis infection in both athymic mice and in recombination-activating gene 1 (RAG1)-deficient mice, further demonstrating the T cell-independent mechanisms of trained immunity. In these studies, the ability of a prior infection to provide protection against infection with unrelated pathogens was dependent on macrophages and on proinflammatory cytokine production. Importantly, a recent study showed that multiple passages of *C. albicans* through the gut of mice, leading to an adaptation of the fungus towards colonisation, results in a stronger capacity to induce trained immunity and improved protection against non-specific infections in a lymphocyte-independent manner.

**Trained immunity in humans.** An increasing body of evidence suggests that trained immunity plays a critical role in humans. First, an extensive collection of epidemiological data argues that live vaccines such as the BCG vaccine, measles vaccine, smallpox vaccine and oral polio vaccine have beneficial, non-specific protective effects against infections other than the target diseases (for a review, see also REF 50). Subsequently, proof-of-principle trials with the BCG vaccine in adults and children demonstrated that this vaccine induces non-specific activation of innate immune cells. Interestingly, both epidemiological and immunological studies have shown that the vaccine effects may last for months, but may also be modified or even reversed when a non-live vaccine is given. Furthermore, BCG vaccination led to protection against microorganisms in models of controlled human infection, such as yellow fever or malaria, and this was associated with an augmented proinflammatory activity of monocytes (BOX 1). Second, certain infections, such as malaria, induce a state of hyper-responsiveness that is functionally equivalent to induction of trained immunity. Finally, there is evidence that BCG vaccination can induce antitumour immune effects leading to the prevention or treatment of malignancies such as bladder cancer, melanoma, leukaemia and lymphoma. Notably, these anticancer effects of BCG seem to be dependent on its capacity to induce trained immunity in monocytes and macrophages.

**Diversity of cells that can develop trained immunity.** The cellular basis of the protection induced by trained immunity during bacterial and fungal infections resides in the functional reprogramming of myeloid cells. Some of the first evidence that macrophages have adaptive features came from investigations of LPS tolerance, which demonstrated that gene-specific chromatin modifications were associated with the silencing of genes coding for inflammatory molecules and the priming of other genes encoding antimicrobial molecules. Subsequent studies showed that exposure of monocytes or macrophages to *C. albicans* or the fungal cell wall component β-glucan enhanced the subsequent response of these myeloid cells to stimulation with unrelated pathogens or pathogen-associated molecular patterns. Induction of trained immunity in monocytes was accompanied by the alteration of several chromatin marks. In addition to the data from infections with bacterial and fungal pathogens, other studies have shown that monocytes or macrophages can mount trained immune responses following infection with parasites. Recent work has shown that DCs can also show immune memory responses. In this regard, DCs isolated from mice exposed to the fungal pathogen *Cryptococcus neoformans* displayed strong interferon-γ (IFNγ) production and enhanced proinflammatory cytokine responses on subsequent challenge, which is indicative of a memory response. These effects were dependent on epigenetic changes and were impaired by the treatment of mice with a histone methyltransferase inhibitor.

Certain viral infections also exert protective effects independently of adaptive immunity. For example, herpesvirus latency increases resistance to the bacterial infection of the immune system. Subsequent risk of secondary infections and other diseases related to decreased activity of the host to maintain homeostasis and prevent tissue damage and organ failure, with the suppression of immunological tolerance, a mechanism that dampens the inflammatory response of the host during infection with unrelated pathogens or pathogen-associated molecular patterns, leading to hyper-responsiveness that is functionally equivalent to induction of trained immunity. Further studies have shown that infections by themselves or the exposure of the immune system to microorganism-derived immune stimulatory agents can provoke not only specific protection against reinfection but also non-specific protection against a subsequent challenge with the same or another pathogen. For example, vaccination with the BCG vaccine was shown to protect animals against secondary infections with *Candida albicans*, *Schistosoma mansoni* and *Mycobacterium tuberculosis*. The non-specific character of the protection argues against a significant role of adaptive immunity for mediating this type of cross protection and suggests activation of rather non-specific protective innate immune mechanisms. The BCG vaccine also protects against lethal candidiasis in SCID mice, which lack functional T cells and B cells. Similarly, a prior mild infection with *C. albicans* protects against the subsequent exposure to a normally lethal candidiasis infection in both athymic mice and in recombination-activating gene 1 (RAG1)-deficient mice, further demonstrating the T cell-independent mechanisms of trained immunity. In these studies, the ability of a prior infection to provide protection against infection with unrelated pathogens was dependent on macrophages and on proinflammatory cytokine production. Importantly, a recent study showed that multiple passages of *C. albicans* through the gut of mice, leading to an adaptation of the fungus towards colonisation, results in a stronger capacity to induce trained immunity and improved protection against non-specific infections in a lymphocyte-independent manner.
promoting trained immunity is particularly relevant for the prevention of child death and morbidity; for instance, providing bacillus Calmette–Guérin (BCG) to low-weight African children at birth rather than in the subsequent weeks or months is associated with a reduction of neonatal mortality by a third. Currently, BCG vaccination is a US Food and Drug Administration-approved treatment modality for bladder cancer, and although advocated for improving the survival of patients in a recent phase III trial, the impact of BCG on survival remains unclear. In a significant development, a treatment for bladder cancer that is approved by the US FDA was studied in a phase III trial and was shown to improve survival rates in patients with advanced disease, highlighting the potential of BCG as a promising therapy.

Regulating trained immunity can be a powerful therapeutic paradigm in different disease contexts. Depending on the condition, it could be beneficial to induce trained immunity to aid specific cancer therapies or to treat the immune paralysis associated with sepsis. Other exciting therapeutic applications would be to inhibit an overly trained innate immune state in chronic inflammatory diseases or to prevent potential detrimental trained immunity in organ transplantation.

Promoting trained immunity is particularly relevant for the prevention of child death and morbidity; for instance, providing bacillus Calmette–Guérin (BCG) to low-weight African children at birth rather than in the subsequent weeks or months is associated with a reduction of neonatal mortality by a third. Also, it could be very relevant in the treatment of cancer and can be achieved by activating certain pattern recognition receptors. Indeed, the first immunotherapeutic strategy in cancer, developed by William Coley at the end of the nineteenth century, induced inflammation and may have been linked to induction of a trained immunity phenotype. After observing spontaneous tumour remission in patients with cancer with concomitant infections, Coley developed a method involving injection of streptococcal organisms into tumours. Despite successful treatment of several patients, Coley’s approach was met with criticism and scepticism because of its unpredictability and the risk of promoting excessive systemic side effects. Given that the host microbiota determines the effectiveness of checkpoint blockade therapy in cancers, it is of particular relevance to mechanistically untangle the effect of the host microbiota on the performance of existing T-cell immunotherapies, chimeric antigen receptor T-cell function may overcome the immunosuppressive microenvironment, facilitating the performance of existing T cell immunotherapies, chimeric antigen receptor T cell therapy and checkpoint inhibitors. Several alternative strategies to activate innate immunity and thereby trained immunity by injecting immunostimulatory agents into tumours are currently being developed together with checkpoint blockade, including activators of the NLRP3, STING, Toll-like receptor and immunostimulatory agents into tumours. Despite successful treatment of several patients, Coley’s approach was met with criticism and scepticism because of its unpredictability and the risk of promoting excessive systemic side effects. Given that the host microbiota determines the effectiveness of checkpoint blockade therapy in cancers, it is of particular relevance to mechanistically untangle the effect of the host microbiota on the effectiveness of trained immunity.

Box 1 | Trained immunity as a therapeutic target

Regulating trained immunity can be a powerful therapeutic paradigm in different disease contexts. Depending on the condition, it could be beneficial to induce trained immunity to aid specific cancer therapies or to treat the immune paralysis associated with sepsis. Other exciting therapeutic applications would be to inhibit an overly trained innate immune state in chronic inflammatory diseases or to prevent potential detrimental trained immunity in organ transplantation.

Promoting trained immunity is particularly relevant for the prevention of child death and morbidity; for instance, providing bacillus Calmette–Guérin (BCG) to low-weight African children at birth rather than in the subsequent weeks or months is associated with a reduction of neonatal mortality by a third. Also, it could be very relevant in the treatment of cancer and can be achieved by activating certain pattern recognition receptors. Indeed, the first immunotherapeutic strategy in cancer, developed by William Coley at the end of the nineteenth century, induced inflammation and may have been linked to induction of a trained immunity phenotype. After observing spontaneous tumour remission in patients with cancer with concomitant infections, Coley developed a method involving injection of streptococcal organisms into tumours. Despite successful treatment of several patients, Coley’s approach was met with criticism and scepticism because of its unpredictability and the risk of promoting excessive systemic side effects. Given that the host microbiota determines the effectiveness of checkpoint blockade therapy in cancers, it is of particular relevance to mechanistically untangle the effect of the host microbiota on the effectiveness of trained immunity. Trained immunity as a therapeutic target

Regulating trained immunity can be a powerful therapeutic paradigm in different disease contexts. Depending on the condition, it could be beneficial to induce trained immunity to aid specific cancer therapies or to treat the immune paralysis associated with sepsis. Other exciting therapeutic applications would be to inhibit an overly trained innate immune state in chronic inflammatory diseases or to prevent potential detrimental trained immunity in organ transplantation.

Promoting trained immunity is particularly relevant for the prevention of child death and morbidity; for instance, providing bacillus Calmette–Guérin (BCG) to low-weight African children at birth rather than in the subsequent weeks or months is associated with a reduction of neonatal mortality by a third. Also, it could be very relevant in the treatment of cancer and can be achieved by activating certain pattern recognition receptors. Indeed, the first immunotherapeutic strategy in cancer, developed by William Coley at the end of the nineteenth century, induced inflammation and may have been linked to induction of a trained immunity phenotype. After observing spontaneous tumour remission in patients with cancer with concomitant infections, Coley developed a method involving injection of streptococcal organisms into tumours. Despite successful treatment of several patients, Coley’s approach was met with criticism and scepticism because of its unpredictability and the risk of promoting excessive systemic side effects. Given that the host microbiota determines the effectiveness of checkpoint blockade therapy in cancers, it is of particular relevance to mechanistically untangle the effect of the host microbiota on the effectiveness of trained immunity.

pathogens Listeria monocytogenes and Yersinia pestis, with protection achieved through enhanced production of IFNγ and systemic activation of macrophages. In the past decade, a unique anamnestic response has been described in natural killer (NK) cells during cytomegalovirus infection. Experimental studies demonstrated that mouse and human NK cells possess adaptive immune characteristics following infection with mouse cytomegalovirus (MCMV) or human cytomegalovirus, respectively. Mouse NK cells bearing the Ly49H receptor possess antigen specificity for MCMV-encoded glycoprotein m157 (Ref. 127), can undergo clonal proliferation (as much as 104-fold expansion from a single NK cell clone)126 and persist during the contraction and memory phases similarly to CD8+ T cells. On reinfection, these memory NK cells undergo a secondary expansion and can more rapidly degranulate and release cytokines, resulting in a more protective immune response against MCMV129,130. In human NK cells, the NKG2C receptor can mediate a similar function through recognition of human cytomegalovirus-encoded UL40 peptides presented on the non-classical MHC molecule HLA-E131. Because these adaptive NK cell responses more closely resemble T cell responses than trained immunity in macrophages, yet occur in the absence of RAG-mediated antigen receptor gene rearrangement, this unique NK cell response may represent an evolutionary bridge between the memory response of T cells and that of myeloid lineage cells.

A response in innate-like lymphocytes that more closely resembles trained immunity is perhaps the non-antigen specific priming of NK cells and innate lymphoid cells (ILCs) by proinflammatory cytokines. Mouse and human NK cells exposed to IL-12 and IL-18 showed more robust production of IFNγ weeks after initial priming132,133, and transplantation of these cytokine-induced memory-like NK cells has shown efficacy in clinical trials to treat leukaemias. Even in the adaptive responses of MCMV-specific NK cells, proinflammatory cytokine signals are critical for the formation of robust effector and memory NK cells137,138. It was recently found that liver-resident group 1 ILCs (ILC1s) also expand and persist after infection with MCMV, acquiring stable transcriptional, epigenetic and phenotypic changes 1 month after the resolution of systemic infection, and showed enhanced memory responses139. In this setting, both proinflammatory cytokines and antigen specificity (NK1.1 receptor-mediated recognition of MCMV-encoded m12) were critical in driving a memory response in ILC1s140. ILC2s have also been suggested to possess features of immunological memory following stimulation with allergens141, perhaps resembling prior studies of hapten-induced priming of NK cells in delayed hypersensitivity responses142. Anamnestic immunity in NK cells may also play an important role in physiological processes such as pregnancy. A recent study showed that NK cells from women who have been repeatedly pregnant show a particular epigenetic and transcriptomic landscape, with open chromatin around the enhancers of IFNγ and VEGFA, improving placentation and supporting vascular sprouting143.

Trained immunity in stromal and epidermal stem cells.

Intriguingly, the induction of innate immune memory is not exclusively confined to immune cells but can also occur in stromal and epithelial cells. The discovery of inflammatory memory behaviour in epidermal stem cells is of particular relevance, as tissue stem cells are the cornerstone of regeneration in homeostasis and they reside in distinct microenvironments or niches and exchange signals that define their tasks and their molecular behaviours. Although the rate of cellular replacement during homeostasis is tissue and context specific, even quiescent stem cells are mobilized into action on tissue injury. Similarly, inflammation and infections perturb the niche microenvironment, which can override the normal homeostatic cues and prompt changes in stem cell behaviours. Thus, through their ability to sense and respond to niche signals, stem cells can adjust to and survive stressful situations. Remarkably, stem cells form an enduring epigenetic memory from such encounters, which equips them with the ability to mobilize more rapidly during subsequent assaults.

Stem cells express receptors for several inflammatory mediators, which enables them to adjust to their specific inflammatory milieu. Moreover, stem cells
are equipped with receptors to sense whether the epithelial barrier is breached and, in turn, actively recruit immune cells to prevent spread of bacteria and to repair the damage. Although it is still unfolding, the molecular communication avenue between stem cells and immune cells appears to be bidirectional. Stem cells do not merely take instructions but rather they also actively instruct the immune system. In the skin, for example, stem cells can sense when their niche barrier is breached and produce signals to recruit specific immune cell sentinels, even under conditions where the immune system itself has been suppressed. In turn, recruited immune cells can signal to stem cells to proliferate and patch the barrier. In this way, the coordination is honed to achieve maximal tissue repair. Another cell type that can acquire a trained immunity-like phenotype is the fibroblast. It was demonstrated that IFNβ treatment of mouse embryonic fibroblasts led to faster and higher induction of interferon-stimulated genes that correlated with enhanced recruitment of polymerase II to interferon-stimulated gene loci on restimulation.

**Central versus peripheral trained immunity**

Trained immunity was initially shown to act through mature myeloid cells. Until recently this hypothesis resulted in a conundrum as mature myeloid cells, such as monocytes and DCs, in both mice and humans are short-lived, with an average half-life of 5–7 days.

Therefore, how trained immunity can be maintained in myeloid cells for several months, years and even decades remained unknown. More recent work has helped to resolve this issue by showing that trained immunity can occur in bone marrow progenitor cells (central trained immunity), as well as in blood monocytes and tissue macrophages (peripheral trained immunity) (Fig. 2).

Recent studies have shown that β-glucan or BCG can reprogramme myeloid progenitors in the bone marrow to generate trained immunity within the myeloid cell compartment. In a mouse model of tuberculosis, Kaufmann and colleagues demonstrated that BCG vaccination reprogrammes haematopoietic stem cells (HSCs) in the bone marrow towards myelopoiesis in an IFNγ-dependent manner, which leads to protective trained immunity. Similarly, β-glucan increases myelopoiesis by promoting the expansion of myeloid-biased CD41+ HSCs and cells from the myeloid-biased multipotent progenitor 3 (MPP3) subset. IL-1β and granulocyte–macrophage colony-stimulating factor (GM-CSF) signalling as well as alterations in glycolysis and cholesterol biosynthesis in bone marrow progenitors are putative mechanisms that have been proposed to explain β-glucan-induced trained immunity in mice.

The discovery that HSCs, similarly to epithelial stem cells, display a memory function could explain the long-standing mystery as to why short-lived immune cells such as monocytes can acquire memory. Indeed, respiratory epithelial progenitors become more stem-like during human allergic inflammatory disease, and the associated accessible chromatin changes differ in their ability to return to normal when the stimulus is withdrawn.

Several studies have furthermore investigated whether trained immunity exists at the level of individual tissues and if so, how these changes are maintained or erased to ensure proper tissue function. Conceivably, tissues exposed to the outside world, such as the skin, the lungs and the intestine, are prone to encounter immune training-inducing stimuli. This concept was explored in the lung using two models of viral challenge: namely, latent gammaherpesvirus infection and adenovirus infection. The severity of house dust mite-induced asthma was decreased in the lungs of mice that had previously been chronically infected with gammaherpesvirus. This phenotype was dependent on the long-term generation and maintenance of monocyte-derived regulatory alveolar macrophages that conferred protection against the development of an allergic response in the lung. Conversely, adenovirus infection induced remodelling in alveolar macrophages, which are long-lived tissue-resident cells, such that they retained the information of an inflammatory history and subsequently

---

**Fig. 2 | Central and peripheral trained immunity.** Although trained immunity was first established in cells of the mononuclear phagocyte lineage (that is, monocytes and macrophages), monocytes have a relatively short lifespan and are unlikely to transmit their memory phenotype to their progeny and provide sustainable protection. Thus, current vaccine strategies that directly target monocytes or macrophages may have limited capacity for generating sustained innate immune memory. By contrast, haematopoietic stem cells (HSCs) are long-lived cells with self-renewal properties that reside in the bone marrow. The bone marrow is the site of haemopoiesis where HSCs continually undergo asymmetric division giving rise to the full repertoire of myeloid and lymphoid cell types. HSCs can directly respond to acute and chronic infections. Although the exact mechanisms of precursor proliferation or differentiation are not well understood, persistent activation of HSCs can result in their exhaustion, leading to devastating effects on the systemic immune compartment. Monocytes derived from trained HSCs migrate to peripheral organs, where they give rise to monocyte-derived macrophages with enhanced effector functions against different types of pathogens. Natural killer (NK) cells possess adaptive immune characteristics following infection. On reinfection, these memory NK cells undergo a secondary expansion and can more rapidly degranulate and release cytokines, resulting in a more protective immune response. Epithelial stem cells show memory functions during human allergic inflammatory disease, displaying changes in the chromatin accessibility when the stimulus is withdrawn. BCG, bacillus Calmette–Guérin; CMP, common myeloid progenitor; GMP, granulocyte–macrophage progenitor; MPP, multipotent progenitor.
induced more pronounced antibacterial immunity\textsuperscript{107}. However, in the case of the adenovirus infection, the tissue-specific training phenotype was dependent on the polarization of CD8\(^+\) T cells by trained alveolar macrophages and therefore provided a link between trained and adaptive immunity. Together, these two recent studies highlight the importance of tissue-specific training cues, which are likely to occur consecutively over an individual’s lifespan, raising the question of how these training cues contribute to protection against infections and the development of inflammatory diseases and cancer.

**Epigenetic reprogramming**

Induction of a trained immune phenotype in innate immune cells enables them to react with stronger, more rapid or qualitatively different transcriptional responses when challenged with subsequent triggers. The molecular basis of this altered responsiveness of a defined subset of inflammatory genes is only partially understood, but evidence supports the convergence of multiple regulatory layers, including changes in chromatin organization at the level of the topologically associated domains (TADs), transcription of long non-coding RNAs (lncRNAs), DNA methylation and reprogramming of cellular metabolism (FIG. 3).

In quiescent myeloid cells, most of the proinflammatory gene loci are in a repressed configuration\textsuperscript{110}, hindering access of the transcriptional machinery to the regulatory regions driving expression of inflammatory factors\textsuperscript{110}. Many studies have demonstrated that stimulation of innate immune cells can leave an ‘epigenetic scar’ at the level of stimulated genes, changing the long-term responsiveness of the cells that manifests itself as functional trained immunity programs. Intrinsically to the presence of such an epigenetic scar is the question of how it is selectively directed to specific locations in the genome, either at the promoters of stimulated genes or at distal regulatory elements. Two key epigenetic marks accompany trained immunity: the acquisition of histone 3 lysine 27 acetylation (H3K27ac) marks at distal enhancers (marked with histone 3 lysine 4 methylation (H3K4me1)) and the consolidation of histone 3 lysine 4 trimethylation (H3K4me3) marks at the promoters of stimulated genes (FIG. 4). Transcription is an inherently stochastic process, which is regulated by several factors, including the random collision of transcription factors with upstream promoter and enhancer DNA regions. However, dynamic loop-mediated regulation and the resulting stochastic responses in gene expression may not be ideal for gene classes that need to respond both immediately and uniformly to external stimuli across cell populations. This suggests that to reduce stochasticity in gene expression, the chromosomal contact between rapidly responding genes may exist in a more stable or preformed state, which strongly implicates the influence of chromosomal looping and TAD structure on this subclass of transcriptional responses. Studies using Hi-C (a method for analysing chromatin interactions) have revealed that several classes of innate immune genes are segregated into TADs and interact within multigene complexes. A recent study demonstrated how TAD structure enables a class of lncRNAs called ‘immune gene-priming lncRNAs’ (IPLs) to be brought into close proximity with transcriptionally poised innate immune genes, before their transcriptional activation\textsuperscript{110}. IPLs exploit preformed 3D looping contacts to bring the H3K4me3 histone-modifying complex close to the promoters of highly responsive innate immune genes, permitting their epigenetic activation and training. The insertion of an IPL in the mouse preformed chemokine TAD confers these genes with the ability to transcriptionally respond rapidly and robustly (uniformly across all cells in the population) and to be accessible to training by β-glucan. The latter is a property they previously did not have in the absence of the IPL\textsuperscript{110}.

As current studies have investigated the role of IPLs only in β-glucan-induced trained immunity phenotypes, further studies are warranted to explore these mechanisms in other experimental settings, including the importance of IPLs during in vivo vaccination.

This functional experiment demonstrates the key role IPLs play in the ‘writing’ of H3K4me3 marks at discrete loci in the genome\textsuperscript{110}. How the H3K27ac mark is directed to specific distal enhancer marks (carrying H3K4me1 epigenetic marks) remains an important outstanding question. It is clear from mouse HSC data that after BCG exposure, the acquisition of open chromatin as measured by assay for transposase-accessible chromatin using sequencing (ATAC-seq) begins in HSCs, and acetylation drives the opening of specific TADs\textsuperscript{111}. The specific locations of these marks are, at least partially, preserved through the differentiation of HSCs into different myeloid and lymphoid lineage cells\textsuperscript{111}. It is likely that in terminally differentiated myeloid cells, the H3K4me1 marks established in the HSC lineage continue to be present, and the gain and loss of H3K27ac occurs in response to exposure to LPS tolerization and β-glucan priming, even though this question remains to be formally analysed and established. The transmission of these marks through DNA replication and the cell cycle is a central conundrum around how trained immunity is stably maintained\textsuperscript{111}. Clearly, an as yet undiscovered mechanism preserves H3K4me1 and H3K4me3 marks through the cell cycle in HSCs.

In the adaptive responses of NK cells, epigenetic control of activation, clonal proliferation, contraction and memory have been demonstrated in the context of viral infection in both humans and mice\textsuperscript{112,113}. Naïve, effector and memory NK cells possess distinct chromatin accessibility states as determined by ATAC-seq and H3K4me3 chromatin immunoprecipitation followed by sequencing, which has revealed a ‘poised’ regulatory programme at the memory NK cell stage following MCMV infection\textsuperscript{111}. Furthermore, concurrent chromatin profiling of the MCMV-specific CD8\(^+\) T cell response demonstrated parallel epigenetic signatures that define memory NK cells and CD8\(^+\) T cells\textsuperscript{113}. Finally, many transcription factors have been identified that promote permissive histone modifications and overall chromatin accessibility at specific loci to drive adaptive NK cell responses, including STAT4, STAT1, ZBTB32, T-bet, EOMES, IRF8, IRF9, KLF12 and RUNX family transcription factors\textsuperscript{105,114–118}.
MicroRNAs might also have a role in the induction and regulation of these mechanisms. miR-155 was shown to be critical for adaptive NK cell responses to MCMV infection through the regulation of targets, including NOXA and SOCS1 (Refs 119,120). The upregulation of miR-155 during inflammatory processes has also been correlated with the hyperactivation of cells from the myeloid compartment. This is likely owing to a decreased activity of phosphatases that act as negative regulators of a series of intracellular pathways121, including the phosphatase SHIP1, which was recently demonstrated to act as a negative regulator in the induction of trained immunity122.

New studies also suggest that changes in DNA methylation patterns discriminate between ‘responders’ (people who are able to undergo trained immunity) and ‘non-responders’ to stimuli that induce trained immunity, such as BCG. In this regard, individuals who exhibit an enhanced containment of M. tuberculosis replication after BCG vaccination displayed a wide loss of DNA methylation among promoters of genes belonging to immune pathways compared with individuals characterized as non-responders123. A follow-up study identified 43 genes with differential methylation patterns in BCG-naive responders compared with non-responders that could potentially be used as predictors of responsiveness to stimuli that induce trained immunity124.

As mentioned earlier, non-haematopoietic cells, such as epidermal stem cells, also show features of trained immunity. The epigenetic memory of epidermal stem cell...
cells is also interesting as certain features of it can still be detected months after the inflammation has resolved. Additionally, the lingering accessible chromatin domains harboured within the epidermal stem cells of inflammation-exposed skin can act as inflammation-sensing enhancers when excised and used to drive reporter expression in the skin in vivo. Thus, although the molecular mechanisms underlying this memory are still unfolding, as they are for inflammatory memories rooted in other cell types, the field is coming to the view that cells and tissues may have evolved to possess memory for the benefit of confronting recurrent disease pathologies and maintaining tissue fitness.

**Immunometabolic circuits**

Cellular metabolism is a critical mediator of the trained immunity-dependent epigenetic reprogramming of innate immune cells and their progenitors. It is well established that metabolites can modulate the activity of chromatin-modifying enzymes; hence, metabolic rewiring of innate immune cells or their progenitors will regulate their plasticity and epigenomic reprogramming in the context of trained immunity. Increased aerobic glycolysis is a hallmark of β-glucan-trained monocytes; this is mediated by a pathway that involves the activity of AKT, mechanistic target of rapamycin (mTOR) and hypoxia-inducible factor 1α (HIF1α). Consistently, blockade of the AKT–mTOR–HIF1α pathway abrogates trained immunity. Furthermore, BCG-induced trained immunity requires the functional reprogramming of monocyte metabolism towards aerobic glycolysis to develop enhanced responsiveness to subsequent stimulation.

Subsequent studies with integrated metabolomic and transcriptomic analyses of human β-glucan-trained monocytes revealed crosstalk between glycolysis and glutaminolysis in trained immunity. Trained monocytes accumulate the tricarboxylic acid cycle (TCA) metabolite fumarate, which influences epigenetic reprogramming by downregulating the activity of KDM5 histone demethylases. Moreover, different TCA intermediates exert distinct effects on innate immune cell activity. For instance, α-ketoglutarate promotes anti-inflammatory activation of macrophages via epigenetic reprogramming that is mediated by the H3K27 demethylase JMID3. Moreover, α-ketoglutarate facilitates endotoxin tolerance after classic LPS-mediated or IFNγ-mediated activation of macrophages.

By contrast, LPS-induced succinate regulates a proinflammatory HIF1α–IL-1β pathway in mouse bone marrow-derived macrophages. The metabolite itaconate, the concentration of which is highly upregulated in LPS-activated macrophages, exerts...
anti-inflammatory activity by inhibiting the succinate dehydrogenase-mediated oxidation of succinate to fumarate\textsuperscript{134,135}. Itaconate itself acts in an anti-inflammatory fashion in macrophages by supporting the activity of the anti-inflammatory transcription factor NRF2 (Ref.\textsuperscript{136}) and the inhibition of LPS-mediated IkB induction. The latter effect of itaconate is independent of NRF2 but requires activating transcription factor 3 (ATF3)\textsuperscript{137}. Of note, itaconate-induced tolerance in human monocytes is counteracted by β-glucan-induced trained immunity as β-glucan inhibits the expression of immune-responsive gene 1 (IRG1) protein, the enzyme responsible for itaconate generation. Consistent with fumarate accumulation in β-glucan-trained monocytes\textsuperscript{138}, β-glucan-mediated inhibition of IRG1 results in elevated expression of succinate dehydrogenase\textsuperscript{139}. Thus, β-glucan-induced trained immunity is associated with enhanced succinate dehydrogenase activity and accumulation of fumarate as well as with reversing the endotoxin tolerance-inducing effects of itaconate, which acts as an antagonist of succinate dehydrogenase.

Enhanced cholesterol synthesis is also an important hallmark of β-glucan-trained monocytes. The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor fluvastatin blocks trained immunity in primary human monocytes\textsuperscript{131}. Interestingly, this is accomplished not by cholesterol biosynthesis but rather by an accumulation of the upstream metabolite mevalonate. Brief exposure to mevalonate can trigger training of monocytes via the insulin-like growth factor 1 receptor and stimulation of mTOR signalling\textsuperscript{132}. Importantly, enhanced cholesterol synthesis is critical for the β-glucan-induced training of not only mature myeloid cells but also of their progenitors (haematopoietic stem and progenitor cells (HSPCs)). The long-term myelopoiesis bias conferred to HSPCs by β-glucan-induced training is associated with accumulation of cholesterol esters and lipids with more saturated acyl chains\textsuperscript{133}. Inhibition of HMG-CoA reductase diminishes β-glucan-induced HSPC population expansion and myelopoiesis\textsuperscript{134}. The enhanced cholesterol levels that occur in HSPCs as a result of innate training may promote a myelopoiesis bias via upregulation of CD131, the common β-subunit of the IL-3/GM-CSF receptor\textsuperscript{135}. This is consistent with findings showing that inhibition of cholesterol efflux in HSPCs, due to deficiency in the ATP-binding cassette transporter ABCA1, also enhances CD131 expression and myelopoiesis in the bone marrow\textsuperscript{136,137}.

Pathological outcomes of trained immunity

Infections were the most common causes of death throughout the world 150 years ago, and they continue to represent the most significant threats to health in low-income countries. Therefore, strong evolutionary pressure has shaped antimicrobial immune functions, including trained immunity. Although trained immunity evolved as a beneficial immune process to protect against infection, one may envisage situations in which reprogramming of innate immunity and increased inflammatory responses to exogenous or endogenous stimuli may also have harmful effects. It is becoming increasingly evident that sterile inflammation in response to lifestyle changes in Western societies forms the basis on which chronic inflammatory diseases develop\textsuperscript{138}. It will thus be necessary to better understand how sterile inflammatory insults induce trained immunity and how trained immunity mechanisms could contribute to chronic inflammation in various diseases associated with Western lifestyle\textsuperscript{139}.

Trained immunity and inflammatory diseases. It is possible that the augmented immune functions arising from trained immunity could lead to pathological tissue damage in certain situations. Trained immunity could, in part, explain the epidemiological link between infections and atherosclerotic cardiovascular disease\textsuperscript{140,141}. In addition to microbial products, endogenous triggers of innate immunity, including oxidized low-density lipoprotein particles, lipoprotein (a), vimentin and high-mobility group box 1 (HMGB1), can induce trained immunity\textsuperscript{142–147}.

Recent work has assessed whether a Western-type diet (that is, a diet enriched in fats, sugars and salt and low in fibre) can induce trained immunity. In atherosclerosis-prone Ldlr\textsuperscript{-/-} mice, 4 weeks of such a Western-type diet induced profound proinflammatory transcriptional and epigenetic reprogramming of circulating monocytes and their bone marrow myeloid progenitor cells. The dietary intervention induced increased inflammatory responses to subsequent innate immune stimuli. This trained immunity phenotype persisted even after the mice had been switched to a standard chow diet for another 4 weeks, despite circulating cholesterol levels and systemic inflammatory markers returning to normal\textsuperscript{148}. Several small proof-of-principle studies in patients suggest that trained immunity also occurs in the setting of dyslipoproteinaemia: monocytes from patients with familial hypercholesterolaemia are characterized by an enhanced cytokine production capacity and enrichment of H3K4me3 on their promoters, which remains present even after 3 months of cholesterol-lowering statin treatment\textsuperscript{149}. Furthermore, circulating monocytes from patients with severe coronary artery atherosclerosis exhibit a trained immune phenotype in terms of enhanced cytokine production capacity and glycolytic metabolism and epigenetic reprogramming at the level of histone methylation\textsuperscript{149,150}.

Another clinical scenario in which sterile endogenous stimuli could trigger trained immunity in monocyte-derived cells is organ transplantation\textsuperscript{151}. Braza et al.\textsuperscript{146} recently showed in a mouse heart transplantation model that donor allografts upregulate vimentin and HMGB1, which induced local training of graft-infiltrating monocyte-derived cells. Short-term treatment with a high-density lipoprotein nanobiologic that specifically inhibited mTOR in myeloid cells was able to prevent aerobic glycolysis and epigenetic modifications underlying trained immunity. The resulting Ly6C\textsuperscript{low} monocyte-derived macrophage-like cells with a regulatory phenotype prevented alloreactive CD8\textsuperscript{T} cell-mediated immunity and promoted tolerogenic CD4\textsuperscript{T} regulatory T cell expansion, which improved allograft survival.
Trained immunity and neurodegenerative diseases. Trained immunity could potentially be important to ameliorate the consequences of immunosenescence, which is associated with the loss of adaptive immune system function. For example, prior BCG vaccination has been shown to enhance antibody responses to many other vaccines that are subsequently administered\(^{151,152}\). On the other hand, there could be negative consequences. Neurodegenerative diseases constitute a significant group of age-related diseases associated with chronic inflammation\(^{153}\). Peripheral application of inflammatory stimuli in a mouse model of Alzheimer disease leads to long-lasting training of microglia, the brain-resident macrophages, which exacerbates cerebral \(\beta\)-amyloidosis\(^{154}\). The functional changes of microglia are accompanied by activating epigenetic changes at the \(HI\) gene locus, consistent with the peripheral trained immunity response\(^{155}\). As a consequence of epigenetic reprogramming, microglia also show changes in transcription and protein expression. Even infections of mice very early in life as a means of immunological training seem to be able to contribute to the impairment of microglial function followed by amyloid-\(\beta\)-induced synapse damage and cognitive impairment\(^{156}\). Together, these studies suggest that systemic inflammation induces microglia reprogramming, resulting in potentially hyper-responsive 'trained' states of the brain immune system.

Another brain pathological abnormality linked to systemic inflammation and associated with dementia is cerebral small vessel disease\(^{157}\). In patients with cerebral small vessel disease, peripheral blood-derived monocytes showed trained immunity characteristics such as enhanced IL-6 and IL-8 production after ex vivo stimulation, which was also associated with the severity and progression of the disease\(^{158}\). A causal link to the pathophysiology of the small vessels in the brain remains to be determined. The pathophysiology of acute stroke is unaltered by prior peripheral immune stimulation\(^{159}\), which might suggest that chronic rather than acute inflammatory conditions are associated with both trained immunity and the induction of neuro-inflammation and neurodegeneration. Accumulating evidence suggests that there is a link between trained immunity and 'inflammageing', the inflammatory condition related to an ageing immune system\(^{160}\). For example, age-related reprogramming of specific innate immune cells might enhance effector mechanisms associated with trained immunity (such as production of IL-8 (REF.\(^{159}\)) and CCL1 (REF.\(^{160}\)), thereby leading to hyper-reactivity. Collectively, a better understanding of the dark side of trained immunity in ageing populations might help us to fight inflammageing-related chronic diseases such as dementia in elderly patients.

Tumour growth and metastasis. Robust and efficient activation of the immune system is fundamental to eliminate cancer cells from the organism. However, excessive or prolonged inflammatory responses can also promote tumour progression as chronic inflammation fuels and sustains disease progression and neoplastic transformation in particular tumour entities. The induction of trained immunity and the metabolic processes in cancer cells share several common features, such as reliance on glycolytic metabolism and the upregulation of the expression and activity of transcription factors such as \(HIF1\alpha\). The induction of trained immunity can be either beneficial or detrimental in the interplay between tumour cells and the cells of the innate immune system.

On the other hand, innate immune cells infiltrating the microenvironment of specific tumours can undergo a reprogramming process that leads to the development of maintained inflammatory responses, so-called smouldering inflammation, that can increase the degree of antigen-driven lymphoproliferation\(^{161}\), impair apoptosis, promote mitochondrial dysfunction and increase oxidative stress in the tumour microenvironment, which ultimately promotes the progression of the tumour. Tumour cells can also reprogramme infiltrating innate immune cells to acquire a more anti-inflammatory phenotype that is reminiscent of the immunoparasitism observed in patients with sepsis; for instance, monocytes from patients with chronic lymphocytic leukaemia show low levels of cytokine production, high phagocytic activity and impaired antigen presentation\(^{162}\). Efficient long-term cell reprogramming is necessary to ensure the efficacy of pharmacological treatments directed against cancer, as shown by the failure of patients with cancer to develop durable responses after treatment with checkpoint inhibitors owing to epigenetic stability of exhausted T cells\(^{163}\). Cytokines such as IL-6 and tumour necrosis factor (TNF) that are produced by trained cells are associated with increased tumorigenicity and the spread of metastases in specific types of tumours, including oral squamous cell carcinoma and lung, kidney and breast cancer\(^{164,165}\). Cancer cells also produce a series of soluble mediators that can induce direct epigenetic and metabolic reprogramming in immune cells and can thereby contribute to the progression of the tumour\(^{166}\).

The data presented above suggest that the ability of immune cells to tune their responses to adapt to changing environments is an important feature that evolved to prepare immune cells for unpredictable events, such as pathogen invasion. However, the epigenetic mechanisms that control the memory of the environmental trigger may also lead to the persistence of pathological responses that drive disease.

Conclusions and future challenges
In this Review, we have presented evidence to suggest that trained immunity, as an epigenetic memory of inflammatory encounters, is a fundamental characteristic of host defence of multicellular organisms, including mammals.

There are many remaining questions and important lines of study that need to be followed in this exciting new field of immunology. One goal should be to describe in more detail the molecular mechanisms that mediate trained immunity. This should involve an exploration of the entire range of immune and non-immune cell populations in which trained immunity can be induced, as well as the precise definition of the immunological, metabolic and epigenetic processes that mediate trained immunity. We need to better understand how
Box 2 | Clinical relevance of inhibiting or reversing trained immunity

Trained immunity is relevant to a range of conditions in which an exacerbated immune response drives disease progression, such as in inflammatory bowel disease, gout, allergy and atherosclerosis and in its clinical consequences, namely myocardial infarction and stroke. Therefore, suppressing ongoing trained immunity or preventing its induction will be a relevant treatment modality for numerous diseases associated with a chronic inflammatory state. In addition, Ochando and colleagues recently implicated trained immunity in organ rejection. Using a trained immunity-inhibiting and mechanistic target of rapamycin (mTOR)-specific nanotherapeutic, they showed that a short treatment regimen resulted in prolonged allograft survival without the need for long-term immunosuppression in a mouse heart transplantation model. Notably, preventing trained immunity rebalanced the myeloid cell compartment from proinflammatory to anti-inflammatory, while the adaptive immune system was characterized by an increased frequency of regulatory T cells. Co-treatment with a nanoimmunotherapeutic agent that prevents CD40–CD40L co-stimulation led to the induction of tolerance. These observations highlight that the innate and adaptive immune systems work in conjunction, and that immune memory can be best considered a feature relevant to phagocytes and lymphocytes.

In addition to targeting myeloid cells metabolic pathways such as the mTOR or hypoxia-inducible factor 1a pathway, inhibiting endogenous mediators of trained immunity such as the NLPR3 inflammasome or IL-1β release is an alternative strategy to suppress trained immunity’s inflammatory component. This was explored in patients with cardiovascular disease in the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS). Finally, regulating epigenetic processes is another compelling therapeutic avenue towards inhibiting trained immunity. Suppression of trained immunity may also be achieved by restricting epigenetic changes with, for example, inhibitors of histone or DNA methylation. Moreover, after the promotion or inhibition of trained immunity, the duration of this phenomenon may be managed by epigenetic modulators that can maintain a certain state of the chromatin in relevant genomic regions. Small molecules that target various epigenetic enzymes (from histone deacetylase inhibitors to modulators of histone methylation and bromodomain inhibitors) are being developed for use in cancer therapy. The applicability of such approaches for other immunemediated diseases is an important area to be investigated soon. Finally, approaches targeting novel compounds to the relevant cell population, especially myeloid cells and their precursors, should be attempted for specific therapy with weak side effects. Bone marrow-targeted nanotherapeutics may offer such a path towards novel therapies.

An important area of future research will be to use the mechanisms induced by trained immunity for the design of a new generation of therapies and vaccines that combine induction of classical adaptive immune memory and trained immunity (BOX 2). The World Health Organization recommends more research into non-specific effects of vaccines; so far, the evidence shows that a vaccination programme that ensures that live vaccines are given would provide optimal specific protection as well as trained immunity, and this would have a substantial impact on overall mortality. Furthermore, new epidemiological study results intriguingly suggest that the non-specific beneficial effects of live vaccines may be amplified if the vaccines are given in the presence of pre-existing immunity, be it from parental priming or from a previous vaccine. Thus, a modified vaccination programme that provides live vaccines earlier, in the presence of maternal immunity, and in multiple doses may lead to increased innate training. Given that trained immunity can induce heightened immune responses, potential non-specific effects of vaccines with regard to chronic inflammatory conditions should be investigated.

Finally, one of the most critical future lines of research is to explore the impact of trained immunity on disease: how does trained immunity contribute to the pathogenesis of immune-mediated diseases on the one hand, and how can trained immunity be approached as a therapeutic target on the other hand? Trained immunity is expected to have an important role both in diseases with impaired host defence, such as postsepsis immune paralysis or cancers, and in autoimmune and autoimmunemediated diseases, in which an exacerbated trained immunity phenotype could contribute to disease pathogenesis. The impact of trained immunity, and more generally of epigenetic rewiring in various processes of priming, adaptation or tolerance during disease, warrants further studies. Also, the role of trained immunity during the ageing process, and the potential association with clonal haematopoiesis, is an important area for future research. On the basis of a profound understanding of these mechanisms, therapeutic applications of the concept of trained immunity are expected to emerge: new generations of vaccines that combine adaptive and innate immune memory; development of inducers of trained immunity for the treatment of immune paralysis in cancer or sepsis; and the modulation of the potentially deleterious consequences of trained immunity in immunomediated and neurodegenerative diseases. Only sustained efforts by the community of researchers working on trained immunity will be able to achieve these aims and fulfill the potential brought by the understanding of the role of trained immunity in health and disease.

Published online 4 March 2020
This study shows that the induction of trained immunity modulates metabolism of haematopoietic progenitors in the bone marrow and increases myelopoiesis.

105. Orovio-Montanes, J. et al. Allergic inflammatory memory in human respiratory epithelial progenitor cells. Nature. 581, 158–162 (2020).

106. This article shows that epithelial stem cells contribute to the persistence of human disease by serving as repositories for allergic memories.

107. Yamaoka, K. et al. NKT cell diversity provides protection against allergic asthma by inducing the replacement of resident alveolar macrophages with regulatory monocytes. Nature. 581, 163–167 (2020).

108. This study shows that the formation and maintenance of alveolar macrophages showing memory features occurs independently of monocytic or bone marrow progenitors.
159. Qian, F. et al. Age-associated elevation in TLR5 leads to increased inflammatory responses in the elderly. Aging Cell 11, 104–110 (2012).

160. Metcalfe, T. U. et al. Global analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors. Aging Cell 14, 421–432 (2015).

161. Hoogeborn, B. et al. A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J. Exp. Med. 210, 59–70 (2013).

162. Jurado-Camino, T. et al. Chronic lymphocytic leukemia: a paradigm of innate immune cross-tolerance. J. Immunol. 194, 719–727 (2015).

163. Pauken, K. E. et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354, 1160–1165 (2016).

164. Lee, S. H. et al. TNFa enhances cancer stem cell-like phenotype via Notch-Hes1 activation in oral squamous cell carcinoma cells. Biochem. Biophys. Res. Commun. 424, 58–64 (2012).

165. Hodge, D. R., Hurt, E. M. & Farrar, W. L. The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 41, 2502–2512 (2005).

166. Rabold, K., Netea, M. G., Adema, G. J. & Netea-Maier, R. T. Cellular metabolism of tumor-associated macrophages: functional impact and consequences. FEBS Lett. 591, 3022–3041 (2017).

167. Cubas, P., Vincent, C. & Coen, E. An epigenetic paradigm of innate immune cross-tolerance. Nature 401, 157–161 (1999).

168. Greer, E. L. et al. A histone methylation network regulates transgenerational epigenetic memory in C. elegans. Cell Rep. 7, 113–126 (2016).

169. Tate, A. T., Andolfatto, P., Demuth, J. P. & Graham, A. L. The within-host dynamics of infection in transgenerationally primed flour beetles. Mol. Ecol. 26, 5794–5807 (2017).

170. No Authors Listed. Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 - conclusions and recommendations. Wkly Epidemiol. Rec. 89, 221–236 (2014).

171. Shann, F. The heterologous (non-specific) effects of vaccines: implications for policy in high-mortality countries. Trans. R. Soc. Trop. Med. Hyg. 109, 5–8 (2015).

172. Benn, C. S., Fisker, A. B., Whittle, H. C. & Aaby, P. Revaccination with live attenuated vaccines confer additional beneficial nonspecific effects on overall survival: a review. EBioMedicine 10, 312–317 (2016).

173. Locht, C. & Mielcarek, N. Live attenuated vaccines against pertussis. Expert. Rev. Vaccines 13, 1147–1158 (2014).

174. Meyers, P. A. et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children’s Oncology Group. J. Clin. Oncol. 26, 633–638 (2008).

175. Muramatsu, D. et al. β-glucan derived from Aureobasidium pullulans is effective for the prevention of influenza in mice. PLoS One 7, e41359 (2012).

176. Mulder, W. J. M., Ochando, J., Joosten, L. A. B., Fayad, Z. A. & Netea, M. G. Therapeutic targeting of trained immunity. Nat. Rev. Drug. Discov. 18, 553–566 (2019).

177. Levine, D. B. The Hospital for the Ruptured and Crippled. William Bradley Coley, third surgeon-in-chief 1925–1935. HSS J. 4, 1–9 (2008).

178. Coley, W. B. B. Contribution to the exhausted T cell field of sarcoma. Ann. Surg. 14, 199–220 (1891).

179. Old, L. J., Clarke, D. A. & Benacerraf, B. Effect of bacillus Calmette-Guérin infection on transplanted tumours in the mouse. Nature 184, 291–292 (1959).

180. Ostadrhami, A. et al. Effect of beta glucan on white blood cell counts and serum levels of IL-4 and IL-12 in women with breast cancer undergoing chemotherapy: a randomized double-blind placebo-controlled clinical trial. Asian Pac. J. Cancer Prev. 15, 5753–5759 (2014).

181. Baster, K. M. B. & Choi, J.-S. Clinical and physiological perspectives of β-glucans: the past, present, and future. Int. J. Mol. Sci. 18, 1906 (2017).

182. Vétvicka, V., Vannucci, L., Sima, P. & Richter, J. Beta glucan: supplement or drug? from laboratory to clinical trials. Molecules 24, 1251 (2019).

183. Lim, W. A. & June, C. H. The principles of engineering immune cells to treat. Cancer Cell 168, 724–740 (2017).

184. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).

185. Routy, B. et al. The gut microbiota influences antitumor immunosurveillance and general health. Nat. Rev. Clin. Oncol. 15, 382–396 (2018).

186. Lamerger, M. et al. Efficacy and safety assessment of a TAF6-targeted nanoinmunotherapy in athrosclerotic mice and non-human primates. Nat. Biomed. Eng. 2, 279–292 (2018).

187. Netea, M. G., Schlitzer, A., Placek, K., Joosten, L. A. B. & Schulte, J. L. Innate and adaptive immune memory: an evolutionary continuum in the host’s response to pathogens. Cell Host Microbe 25, 15–26 (2019).

188. Rubke, P. M. et al. Antiinflammatory therapy with canakinumab for athrothosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).

189. Dominguez-Andrés, J. et al. Bromodomain inhibitor I-BET151 suppresses immune responses during fungal-immune interaction. J. Exp. Med. 49, 2044–2045 (2019).

190. Alqahtani, A. et al. Bromodomains and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci. OA 5, FSO372 (2019).

Acknowledgements
M.G.N. was supported by a Spinoza grant from the Netherlands Organization for Scientific Research and a European Research Council (ERC) Advanced Grant (no. 853247). E. F. is an Investigator of the Howard Hughes Medical Institute and is supported by grants from the US National Institutes of Health (R01-AR15737 and R01-AR050452) and New York State (C32585G5). J.C.S. is supported by the Ludwig Center for Cancer Immunotherapy, the American Cancer Society, the Burroughs Welcome Fund and the US National Institutes of Health (AI100874, AI130045 and P30CA08748). E.L. is supported by grants from the Deutsche Forschungsgemeinschaft (SFBs 645, 670 and 1122, TRR 83 and 57), a grant from the US National Institutes of Health (1R01HL112661) and an ERC Consolidator grant [InflammmAct]. J.L.S is supported by grants from the Deutsche Forschungsgemeinschaft (West German Genome Center grant, Central Coordination Unit of the national Next-Generation Sequencing Competence Network) and grants from the Helmholtz Gemeinschaft (Spares2Big and AmPro) and the European Union (YSYCD, no. 735100). E.L., M.G.N., J.L.S. and A.S. are members of the Immuno-Sensation excellence cluster funded by the Deutsche Forschungsgemeinschaft under Germany’s Excellence Strategy (EXC2151 – 390873048). T.C. is supported by an ERC Consolidator grant [DEMETINL] and by grants from the Deutsche Forschungsgemeinschaft (SFB 1181, TRR-SFB 205 and TRR-SFB 127). N.P.R., L.A.B.J. and M.G.N. received funding from the European Union Horizon 2020 research and innovation programme under grant agreement no. 667837 and the IN-CONTROL grant from the Dutch Foundation Netherlands (CVON2012-05 and CVON2018-27). N.P.R. is a recipient of a grant from European Research Area Network on Cardiovascular Diseases Joint Transnational Call 2018, which is supported by the Dutch Heart Foundation (JTC2018, project MEMORY; 2018T095).

Author contributions
The authors contributed equally to all aspects of the article.

Competing interests
The authors declare no competing interests.

Peer review information
Nature Reviews Immunology thanks H. Goodridge and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© Springer Nature Limited 2020